Axillary radiotherapy was associated with locoregional control comparable to that with axillary lymph node dissection in patients with early-stage breast cancer who had a positive sentinel lymph node biopsy.
Emiel J. T. Rutgers, MD
Emiel J. T. Rutgers, MD
Axillary radiotherapy was associated with locoregional control comparable to that with axillary lymph node dissection (ALND) in patients with early-stage breast cancer who had a positive sentinel lymph node biopsy, according to 10-year data from the phase III AMAROS trial that were presented at the 2018 San Antonio Breast Cancer Symposium (SABCS).1
“The standard paradigm was that if the sentinel node is clean, or only contains minimal disease, then no further axillary surgery is indicated,” said lead investigator Emiel J. T. Rutgers, MD, PhD, in a press conference during SABCS. “If there is cancer, you would need to do complete axillary surgery, and this is associated with adverse events—predominantly lymphedema.”
Prior 5-year follow-up data showed that lymphedema occurred significantly less often in those who received radiotherapy compared with those who underwent ALND. Recent quality-of-life and morbidity data supported the earlier findings, suggesting that radiotherapy can be considered a standard procedure for these patients and an alternative to surgery in this population, Rutgers noted.
For the randomized, multicenter phase III trial, investigators evaluated whether the use of axillary radiotherapy as treatment in women with invasive breast cancer could yield outcomes comparable to those seen when using the traditional ALND approach. Patients with node-negative, invasive breast cancer between 5 mm and 5 cm, and scheduled for breast conservation or mastectomy at any age, with informed consent, were eligible to participate in the trial.
Of the 4806 patients with early-stage, clinically node-negative breast cancer who were enrolled in the trial, 1425 had a positive sentinel lymph node biopsy; of these patients, 744 underwent axillary lymph node dissection, while 681 received axillary radiotherapy.
The baseline age of patients was 56 years (range, 48-64) in the radiotherapy arm and 55 years (range, 48-63) in the surgery arm, and the median tumor size was 17 mm (range, 13-22) and 18 mm (range: 13-23), respectively. Grading was also well-balanced between the groups, Rutgers added. A total 59.2% of those in the radiotherapy arm had received preoperative ultrasound axilla at baseline, compared with 61.5% in the surgery arm.
In terms of baseline treatment, 81.9% of those in the radiotherapy arm underwent breast conservation surgery verses 81.8% in the surgery arm, and 17.1% had a mastectomy in the radiotherapy arm group 17.8% in the surgery arm. Further, both groups received chemotherapy (60.9% in the radiotherapy arm versus 61.3% in the surgery arm), hormonal therapy (78.6% vs 77.1%), and immunotherapy (6.0% vs 6.4%).
The number of sentinel nodes removed was equal between both arms (2; range, 1-3) and 60.5% of patients had macrometastases. “The median number of nodes removed in those who had an axillary clearance was 15, and interestingly, one-third, so 33% [of] patients who had axillary clearance had more positive nodes in the axilla,” Rutgers, a surgical oncologist at the Netherlands Cancer Institute, reported during the press conference.
The first 5-year analysis, published in 2013, did not show any significant differences between the surgery and radiotherapy arms, few relapses in the axilla were observed. However, these results were not universally accepted because the trial was considered underpowered for its noninferior design.
“We needed 52 events, [and at the time of data cutoff] we only had 11,” Rutgers explained. “It would take another 30 years to come up with 52 events, so we presented it as it was. Although it was underpowered, it was clinically very nice for patients, because there were very few events observed.”
After 10 years, the cumulative incidence rate of axillary recurrence was 1.82% (95% CI, 0.74-2.94) in the radiotherapy arm versus 0.93% (95% CI, 0.18-1.68) of the ALND arm (HR, 1.71; 95% CI, 0.67-4.39; P = .365). The number of disease-free survival events was 174 in the ALND arm and 188 in the radiotherapy group (HR, 1.19; 95% CI, .097-1.46; P = .105).
In terms of distant-metastasis free survival or overall survival (OS), the investigators did not observe a significant difference between the 2 treatment arms.
There was a higher 10-year cumulative incidence rate of second primaries with radiotherapy (12.09%; 95% CI, 9.42-14.76) versus ALND (8.33%; 95% CI, 6.14-10.52). Investigators observed a higher incidence of contralateral breast cancer in patients who received radiotherapy.
“We cannot exclude an effect of the radiation to the axilla,” Rutgers said. “But we have to realize that 85% of these patients received radiation therapy anyway because of the breast conservation [surgery], so it’s difficult to see whether the addition of the radiation will lead to more second primary cancers.”
Limitations of the study conclude that the size of the radiation field was greater than what is currently deemed necessary; this resulted in some morbidity that can now potentially be avoided. There was also an imbalance in the number of participants who received a sentinel lymph node biopsy between the arms. In addition, the statistical power of the trial was reduced because there were less recurrences than expected.
Despite these limitations, the investigators conclude that axillary radiotherapy is noninferior to axillary lymph node dissections in terms of locoregional control.
Rutgers, E. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients: 10-year results of the EORTC AMAROS trial. In: Proceedings from the 2018 San Antonio Breast Cancer Symposium; December 4-8; San Antonio, Texas.